Secondary Myelofibrosis Withdrawn Phase 1 Trials for Ruxolitinib (DB08877)

IndicationStatusPhase
DBCOND0030964 (Secondary Myelofibrosis)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02528877Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisSupportive Care